Martin Frost wins “CEO of the Year” at Cambridge Independent Science and Technology Awards 2018

Matt Hancock MP visited the CMR Surgical offices in Cambridge on Thursday.

CAMBRIDGE, UK. 2 November 2018. Martin Frost, CEO of CMR Surgical, has been named CEO of the Year at the Cambridge Independent Science and Technology Awards. The awards, now in their second year, recognise “pioneering start-ups to game-changing leaders in their field”, all based in the region. Martin has successfully led CMR Surgical through an accelerated period of growth as it moves closer to the launch of its next-generation surgical robotic system, Versius®. Martin was responsible for leading a record-breaking Series B funding round in June that raised $100 million; the largest ever Series B raise by a medical devices company in Europe. The strong financial backing of the company will support the introduction of Versius to markets across Europe with wider international expansion thereafter.

Reacting to the award, Martin Frost commented: “I am delighted to collect this award on behalf of everyone at CMR Surgical. I am proud to lead a team that is united behind a single purpose, to make minimal access surgery available to all. I would not be here without the tireless expertise and hard work of such a talented team. I would like to thank each of them for their dedication and commitment.”

CMR Surgical, founded four years ago now employs over 250 people and will shortly be moving to a new 55,000 sq ft global headquarters on the outskirts of Cambridge which will soon become the company’s base for global operations.

— ENDS —

Media Contacts:

For more information, please contact:

Sarah Ghabina / Ashley Davis-Marin
Communications Lead / Senior Communications Executive, CMR Surgical
T +44(0) 1223 755801
E pressoffice@cmrsurgical.com
Notes to editors:

**About CMR Surgical**

CMR Surgical is a British private limited company developing the next-generation universal robotic system, Versius®, for minimal access surgery.

The vision behind CMR Surgical is to make minimal access surgery universally accessible and affordable, transforming the existing market for surgical robotics while also addressing the six million people who still undergo open surgery each year.

Global annual revenues for robot-assisted minimal access surgery are presently approximately $4 billion and are anticipated to reach $20 billion by 2025.¹

CMR Surgical, formed in 2014, has its headquarters in Cambridge, United Kingdom and is backed by an international shareholder base. The Company achieved the registration of its Quality Management System to ISO 13485:2003 by Underwriters Laboratories LLC® (‘UL’), and the status as a UL Registered Firm, in September 2015.

For further information, please visit [www.cmrsurgical.com](http://www.cmrsurgical.com)

**About Versius, the CMR Surgical robotic system**

Designed to meet the complex requirements of laparoscopic surgery, Versius’ compact size fits easily into the existing surgical workflow, while its ergonomic console design allows surgeons to work in a way that reduces physical and mental effort. Intended to be used across a range of surgical specialties, the versatility and portability of Versius, enabled by a unique and patented four-axis wrist joint, expands the potential for higher utilisation. The versatility of the system and compelling commercial model allows healthcare providers to offer the benefits of robotic-assisted procedures in a cost-effective way.

¹ Industry Forecast, Accuray Research